Trial · NCT07886840
Salience Network Informed rTMS for PTSD
NCT07886840, Not applicable, Not yet recruiting, VA Office of Research and Development
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Salience Network Informed rTMS for PTSD. Trials, record NCT07886840. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886840
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Salience Network Informed rTMS for PTSD
- NCT number
- NCT07886840
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 84 participants, estimated
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Active MRI-Guided intermittent theta burst stimulation (iTBS), Sham MRI-Guided intermittent theta burst stimulation (iTBS)
- First posted
- 2026-10-21
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score | Baseline and immediately following completion of treatment (approximately Week 4-6) | The CAPS-5 is a clinician-administered interview used to assess PTSD symptoms according to DSM-5 criteria. Total PTSD symptom severity scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. The outcome is change in CAPS-5 total severity score from baseline to the post-treatment assessment. |
| Primary | Change in Anterior Insula Resting-State Functional Connectivity | Baseline and immediately following completion of treatment (approximately Week 4-6) | Resting-state functional MRI will be used to assess functional connectivity of the anterior insula (aINS). The aINS seed will be defined using the region used for personalized TMS targeting. Functional connectivity is measured as the relationship between the aINS blood-oxygen-level-dependent (BOLD) time series and BOLD time series to the brain. Higher association means higher functional connectivity. The outcome is change in aINS resting-state functional connectivity from the pre-treatment to post-treatment MRI assessment. |
| Secondary | Change in Brain Activation During the Anticipation Task | Baseline and immediately following completion of treatment (approximately Week 4-6) | Task-based functional MRI will be used to assess blood-oxygen-level-dependent (BOLD) activation during the Anticipation task. Higher BOLD response indicates greater activation. The outcome is change in task-related BOLD activation from the pre-treatment to post-treatment MRI assessment. |
| Secondary | Change in Heart Rate Variability | Baseline and immediately following completion of treatment (approximately Week 4-6) | Photoplethysmography (PPG) will be used to derive inter-beat intervals for heart rate variability (HRV) analysis. HRV will be quantified as an index of beat-to-beat variation in cardiac activity. The outcome is change in HRV from the pre-treatment to post-treatment assessment. |
| Secondary | Differential Change in CAPS-5 PTSD Symptom Cluster Severity | Baseline and immediately following completion of treatment (approximately Week 4-6) | The CAPS-5 assesses PTSD symptoms across four DSM-5 symptom clusters: intrusion, avoidance, negative alterations in cognition and mood, and alterations in arousal and reactivity. Symptom severity within each cluster is calculated by summing the CAPS-5 severity ratings for symptoms within that cluster. High scores indicate greater symptom severity. Changes in symptom-cluster severity from baseline to post-treatment will be examined to determine whether treatment effects differ across PTSD symptom clusters. |
| Other | Change in Patient Health Questionnaire-9 (PHQ-9) Total Score | Baseline, post-treatment (Week 4, up to Week 6), and 4-week and 8-week post-treatment follow-ups. | The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure of depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Change in PHQ-9 total score will be assessed from baseline to post-treatment and at 4-week and 8-week post-treatment follow-up assessments. |
| Other | Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score | Baseline, post-treatment (Week 4, up to Week 6), and 4-week and 8-week post-treatment follow-ups | The Generalized Anxiety Disorder-7 (GAD-7) is a 7-item self-report measure of anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be assessed from baseline to post-treatment and at 4-week and 8-week post-treatment follow-up assessments. |
| Other | Change in PTSD Checklist for DSM-5 (PCL-5) Total Score | Baseline, post-treatment (Week 4, up to Week 6), and 4-week and 8-week post-treatment follow-ups | The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure of PTSD symptom severity. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be assessed from baseline to post-treatment and at 4-week and 8-week post-treatment follow-up assessments. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886840
GET https://conductscience.org/api/trials/v1/NCT07886840/registered